BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 35558075)

  • 1. Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets.
    Cai Y; Liu J; Wang B; Sun M; Yang H
    Front Immunol; 2022; 13():856376. PubMed ID: 35558075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc utilization by microglia in Alzheimer's disease.
    Shippy DC; Oliai SF; Ulland TK
    J Biol Chem; 2024 May; 300(5):107306. PubMed ID: 38648940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.
    Streit WJ; Braak H; Xue QS; Bechmann I
    Acta Neuropathol; 2009 Oct; 118(4):475-85. PubMed ID: 19513731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glial cells in Alzheimer's disease: From neuropathological changes to therapeutic implications.
    Uddin MS; Lim LW
    Ageing Res Rev; 2022 Jun; 78():101622. PubMed ID: 35427810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer's disease.
    Wang Z; Weaver DF
    Int Immunopharmacol; 2022 Sep; 110():109070. PubMed ID: 35978514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microglia in Alzheimer's Disease.
    Süß P; Schlachetzki JCM
    Curr Alzheimer Res; 2020; 17(1):29-43. PubMed ID: 32048973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation.
    Anwar S; Rivest S
    Expert Opin Ther Targets; 2020 Apr; 24(4):331-344. PubMed ID: 32129117
    [No Abstract]   [Full Text] [Related]  

  • 8. NLRP1 Inflammasome Activation in the Hippocampal Formation in Alzheimer's Disease: Correlation with Neuropathological Changes and Unbiasedly Estimated Neuronal Loss.
    Španić E; Langer Horvat L; Ilić K; Hof PR; Šimić G
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microglia in Alzheimer's Disease in the Context of Tau Pathology.
    Perea JR; Bolós M; Avila J
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33066368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroinflammation in Alzheimer's Disease: Current Progress in Molecular Signaling and Therapeutics.
    Thakur S; Dhapola R; Sarma P; Medhi B; Reddy DH
    Inflammation; 2023 Feb; 46(1):1-17. PubMed ID: 35986874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neuroprotective N-terminal amyloid-β core hexapeptide reverses reactive gliosis and gliotoxicity in Alzheimer's disease pathology models.
    Lantz MJ; Roberts AM; Delgado DD; Nichols RA
    J Neuroinflammation; 2023 May; 20(1):129. PubMed ID: 37245024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis.
    Lee M; McGeer E; McGeer PL
    Neurobiol Aging; 2015 Jan; 36(1):42-52. PubMed ID: 25169677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DW14006 as a direct AMPKα1 activator improves pathology of AD model mice by regulating microglial phagocytosis and neuroinflammation.
    Lv J; Wang W; Zhu X; Xu X; Yan Q; Lu J; Shi X; Wang Z; Zhou J; Huang X; Wang J; Duan W; Shen X
    Brain Behav Immun; 2020 Nov; 90():55-69. PubMed ID: 32739363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invited Review - Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials.
    Boche D; Nicoll JAR
    Neuropathol Appl Neurobiol; 2020 Dec; 46(7):623-640. PubMed ID: 32643143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microglial Activation and Priming in Alzheimer's Disease: State of the Art and Future Perspectives.
    Bivona G; Iemmolo M; Agnello L; Lo Sasso B; Gambino CM; Giglio RV; Scazzone C; Ghersi G; Ciaccio M
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease.
    Yang J; Wise L; Fukuchi KI
    Front Immunol; 2020; 11():724. PubMed ID: 32391019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Insights into Microglial Mechanisms of Memory Impairment in Alzheimer's Disease.
    Li N; Deng M; Hu G; Li N; Yuan H; Zhou Y
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Microglia in Alzheimer's Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules.
    Althafar ZM
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and Phenotypic Diversity of Microglia: Implication for Microglia-Based Therapies for Alzheimer's Disease.
    Xu YJ; Au NPB; Ma CHE
    Front Aging Neurosci; 2022; 14():896852. PubMed ID: 35693341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.